Information Provided By: 
Fly News Breaks for June 28, 2016
RARE
Jun 28, 2016 | 11:55 EDT
Wedbush analyst Heather Behanna believes the Breakthrough Therapy Designation for KRN23 in pediatric patients with X-linked hypophosphatemia supports Ultragenyx Pharmaceutical's approach. She views the recent weakness in the shares as a buying opportunity and recommends the stock ahead of 2016 catalysts. The analyst reiterates an Outperform rating on Ultragenyx with a $92 price target.
News For RARE From the Last 2 Days
There are no results for your query RARE
